Tarek M. Mekhail, MD

Tarek M. Mekhail, MD

Medical Director (Thoracic Cancer), Medical Oncologist

Cancer

Tarek Mekhail

Overview

Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.

Articles

Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)

ANNALS OF ONCOLOGY

2020

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

SUPPORTIVE CARE IN CANCER

2020

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial

ONCOLOGIST

2019

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria

LANCET ONCOLOGY

2019

IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin plus nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC

CANCER RESEARCH

2019

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol

CLINICAL LUNG CANCER

2019

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

NEW ENGLAND JOURNAL OF MEDICINE

2018

High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer

LUNG CANCER

2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

JOURNAL OF CLINICAL ONCOLOGY

2018

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

CANCER CHEMOTHERAPY AND PHARMACOLOGY

2018

More Publication Information

Education & Training

Education

Cairo University Egypt

Residency

Cleveland Clinic Foundation Ohio

Fellowship

Cleveland Clinic Foundation Ohio

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT03829332

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Icon for trial | MK7902-007 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score

The purpose of this study is to: Test the safety of the study drugs, lenvatinib and pembolizumab, when given together. See how well they work compared to pembrolizumab plus placebo (a lenvatinib look-alike with no active ingred ...

NCT03600883

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects with Advanced NSCLC with KRAS p.G12C Mutation

Icon for trial | 20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subject

This study is currently enrolling.

This study will be conducted in 2 phases: Phase 1 and Phase 2. You will only participate in one phase of the study. The purpose of this Phase 1 study is to see at what dose of AMG 510 is recommended for participants to receive ...

NCT03906071

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Checkpoint INhibitor Therapy (SAPPHIRE)

Icon for trial | 516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy and Checkpoint INhibitor T

This study is currently enrolling.

This study will compare the effectiveness of sitravatinib in combination with nivolumab versus docetaxel in subjects with non-small cell lung cancer who have previously had progression on or after chemotherapy and immunotherapy ...

NCT03138889

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Icon for trial | 16-214-05 A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

This study is currently enrolling.

The purpose of the study is to study how your immune system responds to the investigational drug called bempegaldesleukin (NKTR-214) when it is combined with the approved drug pembroliumab (KEYTRUDA) in patients with locally ad ...

NCT04129502

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Icon for trial | TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

This study is currently enrolling.

The purpose of this study is to determine how safe and how well TAK-788 works as an initial therapy in patients with NSCLC with EGFR exon 20 insertion mutations; the results in these patients will be compared with results in pa ...

NCT04035486

A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor EGFR Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)

Icon for trial | D5169C00001 A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor EGFR Mutation-Positive, Locally Advanced or Metastatic No

This study is currently enrolling.

AstraZeneca AB is doing this research to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for ...

NCT04657991

A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib plus Pembrolizumab versus Placebo plus Pembrolizumab in Participants with BRAF V600E/K Mutation-positive Metastatic or Unresectable Locally Advanced Melanoma

Icon for trial | C4221016 A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib plus Pembrolizumab versus Placebo plus Pembrolizumab in Participants with BRAF V600E/K Mutation-positive Metastatic or Unresectable Locally Advanced Melanoma

This study is currently enrolling.

The purpose of this study is to learn about the effects of the study drugs, encorafenib and binimetinib plus pembrolizumab, and determine the best dose of encorafenib in combination with binimetinib and pembrolizumab that is sa ...

NCT04026412

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Icon for trial | CA209-73L A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Loc

This study is currently enrolling.

The purpose of this study is to evaluate the effectiveness (how well the drug(s) work), safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivoluma ...